Product
Other H1 antagonist
1 clinical trial
1 indication
Indication
Multiple SclerosisClinical trial
A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT)Status: Active (not recruiting), Estimated PCD: 2021-05-04